Glutamate in schizophrenia: A focused review and meta-analysis of 1H-MRS studies

Schizophrenia Bulletin

Volumn 39, Issue 1, 2013, Pages 120-129

  Marsman, Anouk ^a   Van Den Heuvel, Martijn P ^a   Klomp, Dennis W J ^b   Kahn, René S ^a   Luijten, Peter R ^b   Hulshoff Pol, Hilleke E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

aging; glutamatergic system; magnetic resonance spectroscopy

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID;

AGING; BASAL GANGLION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); NEUROTRANSMISSION; OCCIPITAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS;

GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SCHIZOPHRENIA;

EID: 84871840525     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr069     Document Type: Review

References (94)

1. Wright IC, Rabe-Hesketh S, Woodruff PWR, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157:16-25.
2. Van Haren NEM, Hulshoff Pol HE, Schnack HG, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008;63:106-113.
3. Cahn W, Hulshoff Pol HE, Lems EBTE, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry. 2002;59:1002-1010.
4. Borgwardt SJ, McGuire PK, Aston J, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res. 2008;106:108-114.
5. DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr Bull. 2008;34:312-321.
6. Pantelis C, Yü cel M, Wood SJ, McGorry PD, Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust N Z J Psychiatry. 2003;37:399-406.
7. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008;34:354-366.
8. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 1999;122:593-624.
9. Brans RGH, Van Haren NEM, van Baal GC, Schnack HG, Kahn RS, Hulshoff Pol HE. Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia. Arch Gen Psychiatry. 2008;65:1259-1268.
10. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68.
11. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001;11:327-335.
12. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol. 2007;7:39-47.
13. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
14. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
15. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
16. Adams B, Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 1998;18:5545-5554.
17. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33:523-533.
18. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int. 2007;50:291-301.
19. Stone JM, Morrison PD, Pilowsky LS. Review: Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol. 2007;21:440-452.
20. Kaiser LG, Schuff N, Cashdollar N, Weiner MW. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging. 2005;26:665-672.
21. Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol. 2003;65:401-427.
22. Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA. Striatal metabolic alterations in nonpsychotic adolescent offspring at risk for schizophrenia: a 1H spectroscopy study. Schizophr Res. 2009;115:88-93.
23. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry. 2004;161:1116-1118.
24. Yoo SY, Yeon S, Choi CH, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res. 2009;111:86-93.
25. Stone JM, Day F, Tsagaraki H, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 2009;66:533-539.
26. Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1997;54:959-965.
27. Bartha R, Al-Semaan YM, Williamson PC, et al. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry. 1999;45:1403-1411.
28. Bustillo JR, Rowland LM, Mullins P, et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010;15:629-636.
29. Galinska B, Szulc A, Tarasów E, et al. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1HMRS) findings in first-episode schizophrenia. Med Sci Monit. 2009;15:CR82-CR88.
30. Ohrmann P, Siegmund A, Suslow T, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res. 2005;73:153-157.
31. Ohrmann P, Siegmund A, Suslow T, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41:625-634.
32. Stanley JA, Williamson PC, Drost DJ, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull. 1996;22:597-609.
33. Théberge J, Bartha R, Drost DJ, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159:1944-1946.
34. Théberge J, Williamson KE, Aoyama N, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry. 2007;191:325-334.
35. Wood SJ, Berger GE, Wellard RM, et al. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-na?̈ve and early-treated first episode psychosis. Schizophr Res. 2008;102:163-170.
36. Olbrich HM, Valerius G, Rusch N, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry. 2008;9:59-63.
37. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011;69:19-27.
38. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry. 2007;62:1396-1404.
39. Choe BY, Kim KT, Suh TS, et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol. 1994;1:211-216.
40. Lutkenhoff ES, van Erp TG, Thomas MA, et al. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15:308-318.
41. Ö ngü r D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64:718-726.
42. Tayoshi S, Sumitani S, Taniguchi K, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108:69-77.
43. Tebartz van Elst L, Valerius G, Büchert M, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry. 2005;58:724-730.
44. Théberge J, Al-Semaan Y, Williamson PC, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry. 2003;160:2231-2233.
45. Rüsch N, Tebartz van Elst L, Valerius G, et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res. 2008;99:155-163.
46. Shirayama Y, Obata T, Mathalon DH, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage. 2010;49:2783-2790.
47. Wood SJ, Yü cel M, Wellard RM, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3áT. Schizophr Res. 2007;94:328-331.
48. Reid MA, Stoeckel LE, White DM, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2010;68:625-633.
49. Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW. White matter alterations in deficit schizophrenia. Neuropsychopharmacology. 2008;34:1514-1522.
50. Lipsey MW, Wilson DB. The way in which intervention studies have "personality" and why it is important to meta-analysis. Eval Health Prof. 2001;24:236-54.
51. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
52. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York, NJ: Academic Press; 1985.
53. ComprehensiveMeta-analysis.A Computer Program for Research Synthesis [Computer Program]. Englewood, NY; BioStat, Inc. 1999.
54. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
55. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
56. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods. 2006;11:193-206.
57. Olson DP, Hirashima F, Yurgelun-Todd DA, Renshaw PF. Relaxation effects in spectroscopic studies of schizophrenia. In: Ng V, Barker GJ, Hendler T, eds. Psychiatric Neuroimaging. Amsterdam, The Netherlands: IOS Press; 2003:79-185.
58. McLoughlin GA, Ma D, Tsang TM, et al. Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res. 2009;8:1943-1952.
59. Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at 7T. Magn Reson Med. 2001;46:451-456.
60. Steen RG, Hamer RM, Lieberman JA. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and metaanalysis. Neuropsychopharmacology. 2005;30:1949-1962.
61. Gaisler-Salomon I, Miller GM, Chuhma N, et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology. 2009;34:2305-2322.
62. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98:641-653.
63. Iltis I, Koski DM, Eberly LE, et al. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized 1H MRS study. NMR Biomed. 2009;22:737-744.
64. Rowland LM, Bustillo JR,Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162:394-396.
65. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999;98:427-436.
66. Duncan GE, Moy SS, Perez A, et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res. 2004;153:507-519.
67. Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;87:1327-1338.
68. Nakazawa K, Sun LD, Quirk MC, Rondi-Reig L, Wilson MA, Tonegawa S. Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience. Neuron. 2003;38:305-315.
69. Niewoehner B, Single FN, Hvalby Ø, et al. Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eu J Neurosci. 2007;25:837-846.
70. Cheli V, Adrover M, Blanco C, et al. Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning.JNeurochem. 2006;97(suppl 1):68-73.
71. Inada K, Ishigooka J, Anzai T, Suzuki E, Miyaoka H, Saji M. Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory. Neurosci Res. 2003;45:473-481.
72. Inta D, Monyer H, Sprengel R, Meyer-Lindenberg A, Gass P. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci Biobehav Rev. 2010;34:285-294.
73. Bannerman DM, Niewoehner B, Lyon L, et al. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J Neurosci. 2008;28:3623-3630.
74. Sakimura K, Kutsuwada T, Ito I, et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor [epsi]1 subunit. Nature. 1995;373:151-155.
75. Brigman JL, Feyder M, Saksida LM, Bussey TJ, Mishina M, Holmes A. Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit. LearnMem. 2008;15:50-54.
76. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology. 2006;31:2405-2414.
77. Spooren W, Mombereau C, Maco M, et al. Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition. Psychopharmacology. 2004;175:99-105.
78. von Engelhardt J, Doganci B, Jensen V, et al. Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron. 2008;60:846-860.
79. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008;31:234-242.
80. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372-1376.
81. Fuchs EC, Zivkovic AR, Cunningham MO, et al. Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior. Neuron. 2007;53:591-604.
82. Gray L, Van den Buuse M, Scarr E, Dean B, Hannan AJ. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45-60.
83. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;75:889-907.
84. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107.
85. Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- Amino-2-sulfonylbicyclo[ 3.1.0]hexane-4,6-dicarboxylic Acid (LY404039). J Pharmacol Exp Ther. 2008;326:209-217.
86. Szumlinski KK, Lominac KD, Kleschen MJ, et al. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav. 2005;4:273-288.
87. Miyakawa T, Leiter LM, Gerber DJ, et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA. 2003;100:8987-8992.
88. Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry. 2008;63:766-775.
89. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport. 2001;12:2885-2887.
90. Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia. Bipolar Disord. 2009;11:711-25.
91. Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res. 2010;117:92-98.
92. Jensen JE, Al-Semaan YM, Williamson PC, et al. Regionspecific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla. Br J Psychiatry. 2002;180:39-44.
93. Jensen JE, Miller J, Williamson PC, et al. Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry. 2004;184:409-415.
94. Miller J, Williamson P, Jensen JE, et al. Longitudinal 4.0 Tesla 31P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiat Res Neuroim. 2009;173:155-157.